bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S2 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
Authors: Wang Lei , Sun Mengting , Li Jinyang , Wan Linghong , Tan Yuting , Tian Shuoran , Hou Yongying , Wu Linyu , Peng Ziyi , Hu Xiao , Zhang Qihua , Huang Zening , Han Mengyi , Peng Shiyin , Pan Yuwei , Ren Yuanfeng , Zhang Mengsi , Chen Dongfeng , Liu Qin , Li Xianfeng , Qin Zhong-yi , Xiang Junyv , Li Mengxia , Zhu Jianwu , Chen Qiyue , Luo Huiyan , Wang Shunan , Wang Tao , Li Fan , Bian Xiu-wu , Wang Bin
Published: January 2025

Single cell transcriptome analysis of gastric adenocarcinoma tissues
Supplementary Figure S1 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
Authors: Wang Lei , Sun Mengting , Li Jinyang , Wan Linghong , Tan Yuting , Tian Shuoran , Hou Yongying , Wu Linyu , Peng Ziyi , Hu Xiao , Zhang Qihua , Huang Zening , Han Mengyi , Peng Shiyin , Pan Yuwei , Ren Yuanfeng , Zhang Mengsi , Chen Dongfeng , Liu Qin , Li Xianfeng , Qin Zhong-yi , Xiang Junyv , Li Mengxia , Zhu Jianwu , Chen Qiyue , Luo Huiyan , Wang Shunan , Wang Tao , Li Fan , Bian Xiu-wu , Wang Bin
Published: January 2025

Flow diagram of trial enrollment and analysis
Supplementary Data S1 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
Authors: Wang Lei , Sun Mengting , Li Jinyang , Wan Linghong , Tan Yuting , Tian Shuoran , Hou Yongying , Wu Linyu , Peng Ziyi , Hu Xiao , Zhang Qihua , Huang Zening , Han Mengyi , Peng Shiyin , Pan Yuwei , Ren Yuanfeng , Zhang Mengsi , Chen Dongfeng , Liu Qin , Li Xianfeng , Qin Zhong-yi , Xiang Junyv , Li Mengxia , Zhu Jianwu , Chen Qiyue , Luo Huiyan , Wang Shunan , Wang Tao , Li Fan , Bian Xiu-wu , Wang Bin
Published: January 2025

Study Protocol
Supplementary Figure S4 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Authors: Cote Gregory M. , Kochupurakkal Bose S. , Do Khanh , Bullock Andrea , Cheng Michael L. , Muzikansky Alona , McLoughlin Daniel E. , Cleary James M. , Gao Xin , Parikh Aparna , Park Jong Chul , Weekes Colin D. , Yeku Oladapo , Zou Lee , Shapiro Geoffrey I.
Published: January 2025

Figure S4. H-score of pre- and on-treatment biopsy stained with anti-SLFN11 antibody for each patient is shown. Patients from cohort 4 was not included in the analysis. Patients from T4 was not included in this analysis.
Supplementary Figure S3 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Authors: Cote Gregory M. , Kochupurakkal Bose S. , Do Khanh , Bullock Andrea , Cheng Michael L. , Muzikansky Alona , McLoughlin Daniel E. , Cleary James M. , Gao Xin , Parikh Aparna , Park Jong Chul , Weekes Colin D. , Yeku Oladapo , Zou Lee , Shapiro Geoffrey I.
Published: January 2025

Figure S3: (A) Kaplan-Meier plot for PFS vs time on study where patients were stratified based on p53 status of the tumor. The p53 status was available for 15 patients in the study. Patients from T4 was not included in this analysis.
Supplementary Figure S2 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Authors: Cote Gregory M. , Kochupurakkal Bose S. , Do Khanh , Bullock Andrea , Cheng Michael L. , Muzikansky Alona , McLoughlin Daniel E. , Cleary James M. , Gao Xin , Parikh Aparna , Park Jong Chul , Weekes Colin D. , Yeku Oladapo , Zou Lee , Shapiro Geoffrey I.
Published: January 2025

Figure S2: Plot showing the H-score of pCHK1 levels in the pre- and on-treatment biopsy for each patient
Supplementary Figure S1 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Authors: Cote Gregory M. , Kochupurakkal Bose S. , Do Khanh , Bullock Andrea , Cheng Michael L. , Muzikansky Alona , McLoughlin Daniel E. , Cleary James M. , Gao Xin , Parikh Aparna , Park Jong Chul , Weekes Colin D. , Yeku Oladapo , Zou Lee , Shapiro Geoffrey I.
Published: January 2025

Figure S1: (A) Study schema. Patients were recruited into one of four cohorts based on NGS or IHC. Patients received twice-per week infusions of berzosertib at the recommended phase 2 dose. Paired biopsies were collected for cohorts 1 to 3 for translational studies. Six patients were allowed per cohort; however, patients could be replaced if paired biopsies were unsuccessful. *For cohort T3, gene alterations included: germline BRCA1/2 mutations, other homologous repair (HR) alterations (e.g., somatic BRCA1/2, BARD1, BRIP1, CDK12, CHEK2, FANCA, FANCC, FANCE, FANCF, FANCM, MRE11A, NBN, PALB2, RAD51B, RAD51C and RAD51D), MYC amplification, FBXW7 truncating or missense mutations, CCNE1 amplification, ARID1A mutations. (B) Kaplan-Meier plot showing Progression free survival of patients in each cohort
Supplemental Table 1 from Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Authors: Meador Catherine B. , Digumarthy Subba R. , Yeap Beow Y. , Hung Yin P. , Mino-Kenudson Mari , Farago Anna F. , Heist Rebecca S. , Marcoux J. Paul , Rangachari Deepa , Barbie David A. , Piotrowska Zofia
Published: January 2025

Supplemental Table 1. Dose Reductions.
Supplemental Figure 3 from Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Authors: Meador Catherine B. , Digumarthy Subba R. , Yeap Beow Y. , Hung Yin P. , Mino-Kenudson Mari , Farago Anna F. , Heist Rebecca S. , Marcoux J. Paul , Rangachari Deepa , Barbie David A. , Piotrowska Zofia
Published: January 2025

Supplemental Figure 3. Immunohistochemical molecular subtyping of SCLC tumors.
Supplemental Data 1 from Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Authors: Meador Catherine B. , Digumarthy Subba R. , Yeap Beow Y. , Hung Yin P. , Mino-Kenudson Mari , Farago Anna F. , Heist Rebecca S. , Marcoux J. Paul , Rangachari Deepa , Barbie David A. , Piotrowska Zofia
Published: January 2025

Supplemental Data 1. Study Protocol.
Supplementary Table 7 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 7. Normalized gene expression values of the 10% most variable genes in tumor specimens from Patient 3.
Supplementary Table 6 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 6. Normalized gene expression values of the 10% most variable genes in tumor specimens from Patient 2.
Supplementary Table 5 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 5. Normalized gene expression values of the 10% most variable genes in tumor specimens from Patient 1.
Supplementary Table 4 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 4. RNA-seq paired reads mapped to protein coding genes in 31 specimens from 20 primary desmoid tumors.
Supplementary Table 3 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 3. Number of somatic non-synonymous variants detected in each specimen in exome sequencing data.
Supplementary Table 2 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 2. DNA copy number alterations detected in primary and recurrent tumor specimens of 3 patients.
Supplementary Table 15 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 15. Expression of MLH1, MSH2, MSH6 and PMS2 proteins evaluated by immunohistochemistry in duplicate cores of primary and recurrent tumor specimens obtained from 2 patients.
Supplementary Table S1 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Authors: Yu Guopan , Zhang Yu , Yu Sijian , Yin Zhao , Weng Guangyang , Xu Na , Du Xin , Lin Dongjun , Xiao Jie , Sun Zhiqiang , Zhang Hongyu , Liang Xinquan , Guo Ziwen , Zhao Weihua , Dai Min , Fan Zhiping , Xuan Li , Liu Hui , Xu Dan , Ye Jieyu , Jiang Xuejie , Shi Pengcheng , Jin Hua , Liu Qifa
Published: January 2025

Supplementary Table S1. Genetic characteristics according to treatment group.
Supplementary Table 14 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 14. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 2 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).
Supplementary Figure S5 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Authors: Yu Guopan , Zhang Yu , Yu Sijian , Yin Zhao , Weng Guangyang , Xu Na , Du Xin , Lin Dongjun , Xiao Jie , Sun Zhiqiang , Zhang Hongyu , Liang Xinquan , Guo Ziwen , Zhao Weihua , Dai Min , Fan Zhiping , Xuan Li , Liu Hui , Xu Dan , Ye Jieyu , Jiang Xuejie , Shi Pengcheng , Jin Hua , Liu Qifa
Published: January 2025

Supplementary Figure S5. Incorporating HHT to overcome VEN resistance.
Supplementary Table 13 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 13. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 1 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).
Supplementary Table 12 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 12. Validation of clonal and subclonal variants detected in exome sequencing data of Patients 1 and 2 using RNA-seq data.
Supplementary Table 11 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 11. Expression of EFL1, HDAC6, TFG, and hnRNPC proteins evaluated by immunohistochemistry in duplicate cores of primary tumor specimens obtained from 14 patients.
Supplementary Table 10 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Authors: De Bellis Chelsea , Vennam Sujay , Eeles Christopher , Rahimizadeh Pegah , Cates Justin , Stricker Thomas , Hoffman Jenny , Ganjoo Kristen , Charville Gregory W. , Haibe-Kains Benjamin , van de Rijn Matt , Przybyl Joanna
Published: January 2025

Supplementary Table 10. Summary of selected clinicopathological features of patient cohorts in the present study (De Bellis et al.) and in the previous studies published by Salas et al. and Kohsaka et al.
Supplementary Video S1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

Supplementary Video S1. High lesion score mouse: visible bulging lesion with overlaying fluorescence signals as alpha blending in the green channel of the color RGB image. Left, white light imaging; middle, fluorescence imaging; right, overlay imaging.
Supplementary Table S2 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

Supplementary Table S2. Tissue Microarray Metadata (merged data from 4 TMAs used in the study): Impact of stage, T-stage, N-stage, and tumor grade on c-MET positivity and H-score of EAC samples.
Supplementary Figure S5 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

Supplementary Figure S5. Gross anatomy of mouse stomach.
Supplementary Figure S4 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

Supplementary Figure S4. Fluorescence molecular endoscopy study schema.
Figure 3 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

In vivo and ex vivo fluorescence imaging of EMI-137 in the dual xenograft model: A,In vivo fluorescence imaging 3 hours p.i. of EMI-137 showed a strong signal in the OE33 xenograft (right flank, white circle) but not in the FLO-1 xenograft (left flank, gray circle). B, Uptake of EMI-137 in OE33 tumors is effectively but not completely suppressed by coinjecting a 10-fold molar excess of unlabeled EMI-137 as a competitive blocking agent. C, Representative ex vivo tumor and organ panel of the dual xenograft model 3 hours p.i. of EMI-137 showing high uptake in OE33 tumor and kidney. D,Ex vivo tumor and organ panel taken from mice that received EMI-137 plus unlabeled EMI-137 coinjection as a blocking agent. E, Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137. F, Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137 plus a 10-fold molar excess of unlabeled EMI-137 showed more than 50% reduction of fluorescence in OE33 xenograft compared with E. n = 3 mice per group. ****, P < 0.0001. Avg, average; Max, maximum; Min, minimum; ns, not significant.
Figure 1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

c-MET is upregulated in Barrett’s esophagus and esophageal adenocarcinoma compared with normal epithelium: A and B, Upregulation of MET mRNA in Barrett’s esophagus and esophageal adenocarcinoma in two GEO databases in comparison with NSE. C, Representative immunostaining of normal epithelium, inflammation, hyperplasia, and esophageal adenocarcinoma. D, Analysis of human TMAs confirmed upregulation of c-MET protein in esophageal adenocarcinoma compared with NSE, inflammation, and hyperplasia (all P < 0.0001). E and F, Immunostaining of endoscopic human biopsy samples of NSE (n = 6) and Barrett’s esophagus (n = 5) showed an approximately 2-fold greater average H-score and percentage of c-MET positivity in Barrett’s esophagus compared with NSE. **, P < 0.01; ****, P < 0.0001.
Data from Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast
Authors: Huang Huaizhi , Couch Ronan E. , Karam Rachid , Hu Chunling , Boddicker Nicholas , Polley Eric C. , Na Jie , Ambrosone Christine B. , Yao Song , Trentham-Dietz Amy , Eliassen A. Heather , Penney Kathryn , Brantley Kristen , Bodelon Clara , Teras Lauren R. , Hodge James , Patel Alpa , Haiman Christopher A. , John Esther M. , Neuhausen Susan L. , Martinez Elena , Lacey James V. , O’Brien Katie M. , Sandler Dale P. , Weinberg Clarice R. , Palmer Julie R. , Bertrand Kimberly A. , Vachon Celine M. , Olson Janet E. , Ruddy Kathryn E. , Anton-Culver Hoda , Ziogas Argyrios , Goldgar David E. , Nathanson Katherine L. , Domchek Susan M. , Weitzel Jeffrey N. , Kraft Peter , Dolinsky Jill S. , Pesaran Tina , Richardson Marcy E. , Yadav Siddhartha , Couch Fergus J.
Published: January 2025

AbstractPurpose:
To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS).
Experimental Design:
Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort.
Results:
Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years.
Conclusions:
The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Data from Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Winquist Eric , Hotte Sebastien J. , Chi Kim , Sridhar Srikala , Ellard Susan , Ong Michael , Iqbal Nayyer , Salim Muhammad , Emmenegger Urban , Gingerich Joel R. , Lalani Aly-Khan , Major Pierre , Kollmannsberger Christian , Yip Steven , Hansen Aaron , Finch Daygen , Canil Christina , Hutchenreuther James , Vera-Badillo Francisco , Smoragiewicz Martin , Cabanero Michael , Tsao Ming-Sound , Ritch Elie , Wyatt Alexander W. , Seymour Lesley
Published: January 2025

AbstractPurpose:
PD-L1 is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on androgen receptor pathway inhibitors. We tested whether checkpoint blockade could enhance antitumor activity in mCRPC.
Patients and Methods:
In a multicenter open-label noncomparative randomized phase II study, patients with mCRPC treated with ≤1 prior cytotoxic chemotherapy, with measurable disease and progression on abiraterone and/or enzalutamide, were randomized to durvalumab 1,500 mg intravenously every 4 weeks ±4 doses of tremelimumab 75 mg intravenously. The primary endpoint was objective response (OR) by iRECIST using a Simon two-stage design. Correlative testing included PD-L1/cluster designation 8 IHC on baseline tumor biopsies and deep targeted sequencing of plasma cell–free DNA.
Results:
Fifty-two patients were enrolled. Median age was 70 years (range, 50–83 years), and 52% had prior taxane therapy for mCRPC. In stage I, 13 patients were randomized to durvalumab with no OR observed. Durvalumab + tremelimumab advanced to stage II with 39 patients enrolled (receiving a median three cycles, range 1–53). Durvalumab + tremelimumab–related adverse events were mainly ≤ grade 2 but led to discontinuation in seven patients. There were seven ORs [19.4% (95% confidence interval: 8.2%–36.0%); intention to treat 17.9% (95% confidence interval: 7.5%–33.5%)]. Five responding tumors were PD-L1–positive and two exhibited DNA damage repair defects. Responses were observed without high tumor mutational burden or other genomic indices of immunotherapy sensitivity.
Conclusions:
Durvalumab + tremelimumab is active in mCRPC, but patient selection remains a challenge. Further studies to develop predictive biomarkers are warranted.
Data from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Authors: Chauhan Pradeep S. , Alahi Irfan , Sinha Savar , Ledet Elisa M. , Mueller Ryan , Linford Jessica , Shiang Alexander L. , Webster Jace , Greiner Lilli , Yang Breanna , Ni Gabris , Dang Ha X. , Saha Debanjan , Babbra Ramandeep K. , Feng Wenjia , Harris Peter K. , Qaium Faridi , Duose Dzifa Y. , Alexander Sanchez E. , Sherry Alexander D. , Jaeger Ellen B. , Miller Patrick J. , Caputo Sydney A. , Orme Jacob J. , Lucien Fabrice , Park Sean S. , Tang Chad , Pachynski Russell K. , Sartor Oliver , Maher Christopher A. , Chaudhuri Aadel A.
Published: January 2025

AbstractPurpose:
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms remain ill-understood.
Experimental Design:
We applied targeted cell-free DNA (cfDNA) sequencing to 126 patients with mCRPC from three academic cancer centers and separately performed genome-wide cfDNA methylation sequencing on 43 plasma samples collected prior to the initiation of first-line ARSI treatment. To analyze the genome-wide sequencing data, we performed nucleosome positioning and differential methylated region analysis. We additionally analyzed single-cell and bulk RNA sequencing data from 14 and 80 patients with mCRPC, respectively, to develop and validate a stem-like signature, which we inferred from cfDNA.
Results:
Targeted cfDNA sequencing detected AR/enhancer alterations prior to first-line ARSIs that correlated with significantly worse progression-free survival (P = 0.01; HR = 2.12) and overall survival (P = 0.02; HR = 2.48). Plasma methylome analysis revealed that AR/enhancer lethal mCRPC patients have significantly higher promoter-level hypomethylation than AR/enhancer wild-type mCRPC patients (P < 0.0001). Moreover, gene ontology and CytoTRACE analysis of nucleosomally more accessible transcription factors in cfDNA revealed enrichment for stemness-associated transcription factors in patients with lethal mCRPC. The resulting stemness signature was then validated in a completely held-out cohort of 80 patients with mCRPC profiled by tumor RNA sequencing.
Conclusions:
We analyzed a total of 220 patients with mCRPC, validated the importance of cell-free AR/enhancer alterations as a prognostic biomarker in lethal mCRPC, and showed that the underlying mechanism for lethality involves reprogramming developmental states toward increased stemness.

See related commentary by Nawfal et al., p. 7
Data from BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes
Authors: Lang Min , Chang Long , Cai Hao , Lin He , Liu Zheng-zheng , Duan Ming-hui , Zhou Dao-bin , Cao Xin-xin
Published: January 2025

AbstractPurpose:
Langerhans cell histiocytosis (LCH) is a rare and highly heterogeneous histiocytosis. There are currently few studies examining the correlation between molecular profiling and clinical phenotype or outcomes in adult patients with LCH. The objective of this study was to characterize the genomic landscape of adult LCH and correlate molecular findings with clinical features and patient outcomes.
Experimental Design:
This study included 254 patients, ages ≥18 years, with biopsy-proven LCH from January 2000 to December 2023. All patients underwent next-generation sequencing or fluorescence qPCR for the BRAFV600E mutation. Patient demographics, disease characteristics, and treatments were collected through electronic medical records. Patient outcomes were collected through clinical and telephone follow-up.
Results:
Overall, 254 patients were enrolled. MAPK/PI3K pathway alterations were observed in 77.6% (n = 197) of the patients. BRAFV600E mutation was the most common (30.7%, n = 78), followed by BRAFindel (18.1%, n = 46) and MAP2K1 mutations (12.6%, n = 32). The proportion of BRAFindel was much higher in patients with multisystem (MS) involvement than single-system disease (24.5% vs. 6.6%, P < 0.001). Overall, BRAFindel was associated with inferior overall survival (3-year overall survival 89.6% vs. 99.0%, P = 0.014) and progression-free survival (PFS) (3-year PFS 50.0% vs. 78.6%, P < 0.001). In patients with MS LCH, BRAFindel was associated with worse PFS (3-year PFS 47.8% vs. 76.0%, P = 0.001).
Conclusions:
This large study provides molecular and clinical pathologic characterization of adult LCH. BRAFindel was highly correlated with MS LCH and was associated with worse outcomes.
Data from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
Authors: Wang Lei , Sun Mengting , Li Jinyang , Wan Linghong , Tan Yuting , Tian Shuoran , Hou Yongying , Wu Linyu , Peng Ziyi , Hu Xiao , Zhang Qihua , Huang Zening , Han Mengyi , Peng Shiyin , Pan Yuwei , Ren Yuanfeng , Zhang Mengsi , Chen Dongfeng , Liu Qin , Li Xianfeng , Qin Zhong-yi , Xiang Junyv , Li Mengxia , Zhu Jianwu , Chen Qiyue , Luo Huiyan , Wang Shunan , Wang Tao , Li Fan , Bian Xiu-wu , Wang Bin
Published: January 2025

AbstractPurpose:
Neoadjuvant immunochemotherapy (NAIC) markedly induces pathologic regression in locally advanced gastric adenocarcinoma. However, specific biomarkers are still lacking to effectively identify the beneficiary patients for NAIC.
Patients and Methods:
A prospective, single-arm, phase II study was conducted to treat locally advanced gastric adenocarcinoma with NAIC (NCT05515796). Correlation between clinicopathologic characteristics and neoadjuvant efficacy was investigated. Bulk RNA sequencing data from 104 samples (from 75 patients in two independent cohorts) and single-cell RNA sequencing data from 105 treatment-naïve gastric adenocarcinomas were comprehensively analyzed to decipher the association of epithelial and microenvironmental characteristics and clinical responses.
Results:
The prespecified primary endpoints were achieved: pathologic complete regression rate was 30%, major pathologic regression rate was 43%, and the regimen was well tolerated. Analysis of baseline clinical–pathologic parameters revealed the intestinal subtype of Lauren’s classification as a key feature stratifying patients with increased sensitivity to NAIC. Mechanistically, an increased pool of DNA damage repair–active cancer cells and enrichment of CLEC9A+ dendritic cells in the tumor microenvironment were associated with enhanced responsiveness of the intestinal subtype gastric adenocarcinoma to NAIC. More importantly, an intestinal subtype–specific signature model was constructed by the machine learning algorithm NaiveBayes via integrating the transcriptomic features of both DNA damage repair–active cancer cells and CLEC9A+ dendritic cells, which accurately predicted the efficacy of NAIC in multiple independent gastric adenocarcinoma cohorts.
Conclusions:
Intestinal subtype is a histologic biomarker of enhanced sensitivity of gastric adenocarcinoma to NAIC. The intestinal subtype–specific signature model is applicable to guide NAIC for patients with locally advanced gastric adenocarcinoma.
Data from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Authors: Cote Gregory M. , Kochupurakkal Bose S. , Do Khanh , Bullock Andrea , Cheng Michael L. , Muzikansky Alona , McLoughlin Daniel E. , Cleary James M. , Gao Xin , Parikh Aparna , Park Jong Chul , Weekes Colin D. , Yeku Oladapo , Zou Lee , Shapiro Geoffrey I.
Published: January 2025

AbstractPurpose:
Preclinical studies have identified molecular correlates of sensitivity to ATR inhibition. This translational study was designed to test the ATR inhibitor berzosertib in patients with advanced solid tumors carrying alterations in ATRX, ataxia-telangiectasia–mutated (ATM), genes conferring replication stress (RS), or SDH.
Patients and Methods:
Patients were recruited to four cohorts: T1: ATRX-mutant leiomyosarcoma; T2: ATM-mutant solid tumors; T3: solid tumors with mutations in RS-associated genes; and T4: SDH-deficient gastrointestinal stromal tumors (GIST). Patients were treated with berzosertib 240 mg/m2 intravenously twice per week. Pretreatment and on-treatment biopsies were obtained in cohorts T1 to T3.
Results:
Patients with SDH-mutant GIST had the longest median progression-free survival (PFS; 229 days) with stable disease as the best response. Patients in the other cohorts experienced progressive disease within 4 months. There was no significant difference in PFS comparing outcomes in patients with/without mutations in ATM or RS genes. Decreased pS345-CHK1 levels in on-treatment biopsies indicated target engagement by berzosertib and were accompanied by substantial increases in levels of DNA damage (γ-H2AX) and RS (pKAP1) markers in a subset of patients. However, these biomarker changes did not translate to clinical benefit. In contrast, in cohorts T1 to T3, increased expression of SLFN11 on treatment correlated with clinical benefit (HR = 0.045; 95% confidence interval, 0.005–0.400).
Conclusions:
Across cohorts, only patients with SDH-mutant GIST experienced prolonged disease control. Despite evidence of target engagement, patients enrolled to all other cohorts had short PFS, suggesting rapid adaptation to ATR inhibitor monotherapy. Among these patients, those with tumors expressing SLFN11 during berzosertib exposure derived the most clinical benefit.
Data from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Authors: Yu Guopan , Zhang Yu , Yu Sijian , Yin Zhao , Weng Guangyang , Xu Na , Du Xin , Lin Dongjun , Xiao Jie , Sun Zhiqiang , Zhang Hongyu , Liang Xinquan , Guo Ziwen , Zhao Weihua , Dai Min , Fan Zhiping , Xuan Li , Liu Hui , Xu Dan , Ye Jieyu , Jiang Xuejie , Shi Pengcheng , Jin Hua , Liu Qifa
Published: January 2025

AbstractPurpose:
We investigated whether homoharringtonine (HHT) added to venetoclax plus azacitidine (VA) could improve outcomes and counteract the negative effects of genetic patterns in patients with relapsed/refractory acute myeloid leukemia (RR-AML).
Experimental Design:
A multicenter retrospective cohort study of the response and genetic patterns of response to the VA plus HHT (VAH) versus the VA regimens as salvage treatment in patients with RR-AML was performed. The endpoints were the rates of composite complete remission, measurable residual disease, event-free survival, overall survival, and relapse between VAH and VA groups.
Results:
A total of 321 patients (VAH, n = 172; VA, n = 149) were analyzed. Compared with VA, VAH significantly improved the rates of composite complete remission (44.3% vs. 66.3%; P < 0.001), measurable residual disease negativity (34.8% vs. 59.3%; P = 0.002), prolonged overall survival (median: 15.1 months vs. not reached; P < 0.001), and event-free survival (median: 3.8 vs. 13.0 months; P < 0.001). VAH significantly mitigated the negative impact on VA efficacy of mutated FLT3-ITD/TKD, N/KRAS, and t(8;21)/AML1-ETO, as well as the relatively unfavorable effects of the TET2 and DNMT3A mutations. VAH significantly enhanced the response of patients with nonadverse European LeukemiaNet risk, with a trend toward improved response in those with adverse European LeukemiaNet risk, complex karyotype, and DNMT3A+FLT3+NPM1+. The incidence of grade 3 or higher adverse events was comparable between the two groups.
Conclusions:
Our findings suggest the addition of HHT to VA might enhance response and mitigate the negative impact of certain genetic patterns in RR-AML while being well tolerated.
Data from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A.
Published: January 2025

AbstractPurpose:
Esophageal cancer carries a poor prognosis with a 5-year overall survival of less than 20%. Barrett’s esophagus increases the risk of esophageal adenocarcinoma. The aim of this study was to investigate the ability of EMI-137, a mesenchymal–epithelial transition factor (c-MET)-targeting optical imaging tracer, to detect dysplasia in Barrett’s esophagus.
Experimental Design:
c-MET expression in human esophageal tissue was investigated using Gene Expression Omnibus datasets, tissue microarrays, and Barrett’s esophagus biopsies. EMI-137 was tested in a dual xenograft mouse model bearing OE33 (c-MET high expression) and FLO-1 (c-MET low expression) tumors. Fluorescence molecular endoscopy was performed in a mouse model of Barrett’s-like metaplasia and dysplasia (L2-IL1β). Tumors and organs of interest were evaluated through ex vivo fluorescence imaging.
Results:
MET mRNA expression analyses and c-MET immunostaining confirmed upregulation of c-MET in Barrett’s esophagus and esophageal adenocarcinoma compared with normal epithelium. There was strong accumulation of EMI-137 in OE33 xenografts 3 hours after injection, decreasing by more than 50% on coinjection of a 10-fold molar excess of unlabeled EMI-137. The target-to-background ratio at 3 hours after injection for OE33 and FLO-1 tumors was 10.08 and 1.42, respectively. Fluorescence molecular endoscopy of L2-IL1β mice showed uptake of EMI-137 in dysplastic lesions within Barrett’s esophagus with a target-to-background ratio of 1.9 in vivo and greater than 2 in ex vivo fluorescence imaging.
Conclusions:
EMI-137 accumulates in dysplastic lesions within Barrett’s esophagus and also in c-MET–positive esophageal adenocarcinoma. EMI-137 imaging has potential as a screening and surveillance tool for patients with Barrett’s esophagus and as a means to detecting dysplasia and esophageal adenocarcinoma.
Supplementary Materials 1 from What Is the Cost: Financial Toxicity and Screening Fatigue in Li–Fraumeni Syndrome
Authors: Underkofler Kaylee A. , Thomas Martha H. , Erickson Sarah H. , Panzer Alayna A. , Fitzgibbon Kara S. , Ring Kari L.
Published: January 2025

Supplementary Materials 1: Li Fraumeni Clinic Survey on Experiences with Screening
Data from Automated Breast Density Assessment for Full-Field Digital Mammography and Digital Breast Tomosynthesis
Authors: Jiang Shu , Bennett Debbie L. , Chen Simin , Toriola Adetunji T. , Colditz Graham A.
Published: January 2025

Abstract
Mammographic density is a strong risk factor for breast cancer and is reported clinically as part of Breast Imaging Reporting and Data System (BI-RADS) results issued by radiologists. Automated assessment of density is needed that can be used for both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) as both types of exams are acquired in standard clinical practice. We trained a deep learning model to automate the estimation of BI-RADS density from a prospective Washington University clinic-based cohort of 9,714 women, entering into the cohort in 2013 with follow-up through October 31, 2020. The cohort included 27% non-Hispanic Black women. The trained algorithm was assessed in an external validation cohort that included 18,360 women screened at Emory from January 1, 2013, and followed up through December 31, 2020, that included 42% non-Hispanic Black women. Our model-estimated BI-RADS density demonstrated substantial agreement with the density as assessed by radiologists. In the external validation, the agreement with radiologists for category B 81% and C 77% for FFDM and B 83% and C 74% for DBT shows important distinction for separation of women with dense breast. We obtained a Cohen’s κ of 0.72 (95% confidence interval, 0.71–0.73) in FFDM and 0.71 (95% confidence interval, 0.69–0.73) in DBT. We provided a consistent and fully automated BI-RADS estimation for both FFDM and DBT using a deep learning model. The software can be easily implemented anywhere for clinical use and risk prediction.

Prevention Relevance: The proposed model can reduce interobserver variability in BI-RADS density assessment, thereby providing more standard and consistent density assessment for use in decisions about supplemental screening and risk assessment.
Data from Black Raspberry Modulates Cecal and Oral Microbiomes at the Early Stage of a Dibenzo[def,p]chrysene-Induced Murine Oral Cancer Model
Authors: Zhao Jingcheng , Sun Yuan-Wan , Chen Kun-Ming , Aliaga Cesar , Bisanz Jordan E. , El-Bayoumy Karam
Published: January 2025

Abstract
While tobacco smoking is a risk factor in the development of oral squamous cell carcinoma (OSCC), only a fraction of smokers develop the disease. Compelling evidence shows that microbial community composition is associated with carcinogenesis, suggesting that the microbiome may play a role in cancer development of smokers. We previously showed that black raspberry (BRB) protects against OSCC induced by the tobacco constituent dibenzo[def,p]chrysene (DBP) via alteration of genetic and epigenetic markers in a manner consistent with its cancer preventive activity. In the present study, we conducted a mouse experiment to investigate the effects of BRB and DBP individually and in combination on the oral and gut microbiota. DBP-induced DNA damage in the mouse oral cavity is an essential step for the development of OSCC in mice. 16S rRNA gene sequencing revealed that BRB significantly increased microbial diversity and shifted microbiome composition in the gut and oral cavity, whereas DBP had no significant effect. In both gut and oral microbiota, Akkermansia muciniphila was significantly reduced after BRB treatment; however, this was not consistent with pure culture in vitro assays suggesting that the impact of BRB on A. muciniphila may be mediated through indirect mechanisms including the host or other microbes. Indeed BRB, but not DBP, was found to modulate the growth kinetics of human gut microbes in vitro including lactic acid bacteria and Bacteroides spp. The results of the current study further emphasize the interplay of microbiome and environmental factors in the development and prevention of OSCC.

Prevention Relevance: Our work clearly demonstrates the modulatory impact of BRB on both gut and oral microbiomes within a DBP-induced OSCC mouse model and paves the way for future research examining a causal role of BRB–microbiota interactions at different stages of disease progression.
Figure 4 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
Authors: Sasaki Mariko , Kato Daiki , Yoshida Hiroshi , Shimizu Takafumi , Ogiwara Hideaki
Published: January 2025

Simultaneous inhibition of CBP/p300 in SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells induces apoptosis by downregulating KREMEN2. A, Expression of KREMEN2 mRNA (relative to that in nontreated cells) in SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells treated for 24 hours with the indicated concentrations of CP-C27. Data are presented as the mean ± SD; n = 3 independent experiments. B, Expression of KREMEN2 mRNA (relative to that in siNT-transfected cells) in SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells transfected for 48 hours with the indicated siRNAs. Data are presented as the mean ± SD; n = 3 independent experiments. C, Percentage of annexin V–positive cells within the SMARCA4/SMARCA2-deficient and SS18–SSX fusion cell populations treated for 6 days with the indicated concentrations of CP-C27. Data are presented as the mean ± SD; n = 3 independent experiments. D, Expression of CASP6 mRNA (relative to that in nontreated cells) in SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells treated for 24 hours with the indicated concentrations of CP-C27. Data are presented as the mean ± SD; n = 3 independent experiments. E, Expression of CASP6 mRNA (relative to that in siNT-transfected cells) in SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells transfected for 48 hours with the indicated siRNAs. Data are presented as the mean ± SD; n = 3 independent experiments. F, Expression of CASP6 mRNA (relative to that in siNT-transfected cells) in SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells transfected for 48 hours with the indicated siRNAs. Data are presented as the mean ± SD; n = 3 independent experiments. G, Viability of SMARCA4/SMARCA2-deficient and SS18–SSX fusion cells transfected with the indicated siRNAs. Cells were transfected for 48 hours with the indicated siRNAs. Cells were then reseeded and transfected with the indicated siRNAs for 48 hours. The cells were then reseeded again and incubated for 7 days. Data are presented as the mean ± SEM; n = 3 independent experiments. For all experiments, P values were determined by an unpaired two-tailed Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Essential Workers and Wage Inequality: Wage Differentials before and during the Covid-19 Pandemic, 2006 to 2022
Authors: Janietz Christoph
Published: January 2025

In 2020, several governments declared specific occupations as essential for maintaining the functioning of society in response to the Covid-19 pandemic. A current question in the public debate on fair pay is whether essential workers are sufficiently remunerated. Using data from the Netherlands, I analyze the wages of essential workers relative to other workers before and during the Covid-19 pandemic. Wage decompositions indicate that, between 2006 and 2019, essential workers earned less compared to other workers within higher-paid strata, while they earned more within lower-paid strata of the occupational structure in the Netherlands. These wage differentials are shaped by sex composition and sectoral employment. In addition, I employ a difference-in-differences design based on quarterly data between 2017 and 2022 to assess whether the onset of the Covid-19 pandemic reduced an existing average wage gap in response to an increasing public appreciation of essential work. Results indicate that the collective experience of the Covid-19 pandemic has not benefited essential workers in the short-term.
A hidden treasure along Silk Roads: An unexpected new species of spoon-winged lacewings from Xinjiang, China, and a revision of the genus Brevistoma Tjeder, 1967 (Neuroptera: Nemopteridae)
Authors: ZHENG YUCHEN , NI ZIYANG , ASPÖCK ULRIKE , ASPÖCK HORST , BADANO DAVIDE , NEL ANDRÉ , LIU XINGYUE
Published: January 2025

Nemopteridae (spoon-winged or thread-winged lacewings) is a rare group in China, with significant value of conservation. Here, we report a new species of spoon-winged lacewing species, and the third known from China, namely Brevistoma raksasiae Zheng, Ni & Liu sp. nov. (Nemopteridae: Nemopterinae) from the Turpan Basin in Xinjiang. We also revise the genus Brevistoma Tjeder, 1967, providing redescription of three species: B. bardii (Navás, 1914), B. gallagheri Hölzel, 1999, and B. hackeri Hölzel, 1999. Additionally, we restore the validity of B. bourboni (Navás, 1931) stat. rev. The distribution of the new Brevistoma species is remarkable, as the species of this genus had been recorded in the Arabian Peninsula and North Africa. Our new finding highlights the uniqueness of the insect fauna of the Turpan Basin and its biogeographical connection with the Arabian Peninsula and North Africa.
A new genus and species of lappet moths (Lepidoptera: Lasiocampidae) from Central Asia with notes on the systematics of the family
Authors: BELJAEV EVGENIY A. , GORBUNOV PAVEL YU. , KORB STANISLAV K.
Published: January 2025

A new genus, Zolotuhia gen. nov., with the type species Zolotuhia paradoxa, sp. nov., from Kyrgyzstan, Talassky Mt. Range, is established in the lepidopteran family Lasiocampidae. The new genus is characterized by a surprising mix of features in the appearance, wing pattern, wing venation, male and female genitalia, shared with different groups of lappet moths. Based on the review of morphology in the Chondrosteginae/Poecilocampinae/Macromphaliinae lineage of Lasiocampidae, a tentative morphological phylogeny of the genera in the Chondrosteginae/Poecilocampidae group is proposed and two new synonyms: Chondrostegidae Tutt, 1902, = Poecilocampinae Tutt, 1902, syn. nov., = Trichiurinae Tutt, 1902, syn. nov., is established. The generic composition of Chondrosteginae s.l. is discussed. For Chondrostegoides nobilorum Zolotuhin, 2007 a new combination is established: Trichiurana nobilorum (Zolotuhin, 2007), comb. nov. For the dorsal dilation of the valve sacculus located lateral to juxta in Lasiocampidae, early inappropriately named as “valve saccular lobe”, a new name “dorso-basal saccular lobe” is offered. Some problems in the morphology, phylogeny and systematics of Lasiocampidae are addressed.